Back to results

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Primary Purpose

Essential Hypertension

Status

Completed

Phase

Phase 3

Locations

Japan

Study Type

Interventional

Intervention

TAK-536TCH tablet

TAK-536CCB tablet

HCTZ 12.5 mg tablet

About this trial

This is an interventional treatment trial for Essential Hypertension focused on measuring Pharmacological therapy, Drug Therapy

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements.
The participant signs and dates a written informed consent form prior to the initiation of any study procedures.
The participant has essential hypertension.
The participant has an office sitting systolic blood pressure (SBP) of <180 mmHg and office sitting diastolic blood pressure (DBP) of < 110 mmHg at the start of the run-in period (Week -4). Participants receiving combined therapy with a 3-drug antihypertensive within 4 weeks prior to the start of the run-in period is required to have an office sitting SBP of < 160 mmHg and an office sitting DBP of < 100 mmHg.
The participant's office sitting blood pressure at Week -2 and at the end of the run-in period (Week 0) need to be either:
- Participants without concurrent diabetes mellitus or chronic kidney disease (CKD)*: Sitting SBP of ≥ 140 mmHg or sitting DBP of ≥ 90 mmHg
- Participants with concurrent diabetes mellitus or CKD*: Sitting SBP of ≥ 130 mmHg or sitting DBP of ≥ 80 mmHg.
  - Estimate glomerular filtration rate according to creatinine (eGFRcreat) of <60 mL/min/1.73 m^2, or urinary albumin (spot urine) of ≥30 μg/mL in laboratory tests performed at Week -2 of the run-in period, and diagnosed with CKD by the investigator or subinvestigator.
The participant has an office sitting SBP of < 160 mmHg and office sitting DBP of < 100 mmHg at the end of the run-in period (Week 0).
The participant is male or female, aged 20 years or older at the time of providing informed consent.
The participant is an outpatient.
A female participant of childbearing potential who is sexually active with a nonsterilized male partner agree to use routinely adequate contraception from signing of informed consent through 1 month following the end of the study.

Exclusion Criteria:

The participant has received any study drugs within 12 weeks prior to the start of the run-in period.
The participant has participated in another clinical study or a post-marketing study within 30 days prior to the start of the run-in period.
The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g. spouse, parent, child, sibling), or may consent under duress.
The participant requires taking prohibited concomitant drugs during the study.
The participant has a history of hypersensitivity or allergies to TAK-536, AML, HCTZ, any thiazide diuretic or analog, any dihydropyridine drug, or any analog of TAK-536TCH.
The participant is judged by the investigator or subinvestigator to be in danger of experiencing an excessive increase in blood pressure when changing or discontinuing premedication.
The participant received combination therapy with antihypertensive drugs of the 3 ingredients contained in TAK-536TCH.
The participant received combined therapy with antihypertensive drugs, including 4 or more components, within 4 weeks prior to the start of the run-in period.
The participant has secondary or malignant hypertension.
The participant has a difference of ≥ 20 mmHg between left and right arms in office sitting SBP at the start of the run-in period (Week -4).
The participant has apparent white coat hypertension or exhibits a white coat effect.
. The participant has a day-night reversed lifestyle, such as those working during the night.
The participant has sleep apnea syndrome requiring treatment.
The participant has any of the following cardiovascular diseases:
- Cardiac disease: Myocardial infarction*, coronary arterial revascularization*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia
- Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage*, transient ischemic attack*
- Vascular disease: Peripheral artery disease with intermittent claudication, artery dissection, aneurysm
- Advanced hypertensive retinopathy: With bleeding or exudate/papilledema** * Occurring or performed within 24 weeks of the start of the run-in period ** Observed within 24 weeks of the start of the run-in period
The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN).
The participant has a clinically severe renal disorder (e.g., eGFRcreat in laboratory tests performed at Week -2 of run-in period < 30 mL/minute/1.73 m^2).
The participant's body fluid sodium or potassium level is markedly low* or high*.
*Based on normal ranges
The participant has gout or a history of gout within 24 weeks of the start of the run-in period or has hyperuricemia requiring drug treatment.
The participant has uncontrolled diabetes (e.g., HbA1c ≥ 7.4% in laboratory tests performed at Week -2 of the run-in period).
The participant has a malignant tumor.
If female, the participant is pregnant or lactating or before giving informed consent, intending to become pregnant or donate ova during or within 1 month after participating in the study.
The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the run-in period.
The participant who, in the opinion of the investigator or subinvestigator, is unsuitable for any other reason.

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TAK-536TCH

Arm Description

For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast. For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast.

Outcomes

Primary Outcome Measures

Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Number of Participants With Markedly Abnormal Vital Signs Values

Vital signs included supine and standing systolic and diastolic blood pressure (SBP and DBP) respectively and office sitting pulse. Vital signs were considered abnormal if they were beyond the values defined in categories.

Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Body Weight

Reported TEAE is categorized into investigations System Organ Class (SOC) related to body weight.

Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Electrocardiogram (ECG)

Reported TEAE is categorized into cardiac disorders and investigations system organ class (SOC) related to ECG.

Number of Participants With Markedly Abnormal Clinical Laboratory Tests

The number of participants with any markedly abnormal clinical laboratory test values collected throughout study. RBC = Red blood cells, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit. Laboratory vallues were considered abnormal if they were beyond the values defined in categories.

Secondary Outcome Measures

Change From Baseline in Office Trough Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit

The change in office trough SBP and DBP measured at Weeks 12 last observation was carried forward (LOCF) and 52 (LOCF) relative to baseline. Sitting blood pressure was measured at least 3 times. Each measurement session ended once blood pressure was found stable at 2 consecutive measurements. The average of the last 2 measurements of office sitting blood pressure was used.

Change From Baseline in Home Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit

The change in home morning SPB and DBP measured at End of Week 12, End of Treatment (Up to Week 52) relative to baseline.

Full Information

NCT ID

NCT02277691

First Posted

October 27, 2014

Last Updated

June 26, 2017

Sponsor

Takeda

1. Study Identification

Unique Protocol Identification Number

NCT02277691

Brief Title

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Official Title

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

Study Type

Interventional

2. Study Status

Record Verification Date

June 2017

Overall Recruitment Status

Completed

Study Start Date

November 7, 2014 (Actual)

Primary Completion Date

April 25, 2016 (Actual)

Study Completion Date

April 25, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Takeda

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

Detailed Description

The drug being tested in this study is called TAK-536TCH. TAK-536TCH is being tested to treat people who have essential hypertension. The study looked at effectiveness and long-term safety of TAK-536TCH in people who took TAK-536CCB in addition to standard care. The study enrolled 341 patients. Participants received: TAK-536CCB (as TAK-536/AML, 20 mg/5 mg) in run-in period, TAK-536TCH (as TAK-536/ AML/HCTZ, 20 mg/5 mg/12.5 mg) in treatment period TAK-536CCB and HCTZ 12.5 mg in treatment period All participants were asked to take tablets at the same time each day throughout the study. This multi-center trial was conducted in Japan. The overall time to participate in this study was 56 weeks (4 weeks run-in period and 52 weeks treatment period). Participants made multiple visits to the clinic during the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Essential Hypertension

Keywords

Pharmacological therapy, Drug Therapy

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

341 (Actual)

8. Arms, Groups, and Interventions

Arm Title

TAK-536TCH

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

TAK-536TCH tablet

Intervention Description

TAK-536TCH tablets

Intervention Type

Drug

Intervention Name(s)

TAK-536CCB tablet

Intervention Description

TAK-536CCB tablets

Intervention Type

Drug

Intervention Name(s)

HCTZ 12.5 mg tablet

Intervention Description

HCTZ tablets

Primary Outcome Measure Information:

Title

Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Description

Time Frame

Baseline up to Week 52

Title

Number of Participants With Markedly Abnormal Vital Signs Values

Description

Time Frame

Baseline up to Week 52

Title

Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Body Weight

Description

Reported TEAE is categorized into investigations System Organ Class (SOC) related to body weight.

Time Frame

Baseline up to Week 52

Title

Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Electrocardiogram (ECG)

Description

Reported TEAE is categorized into cardiac disorders and investigations system organ class (SOC) related to ECG.

Time Frame

Baseline up to Week 52

Title

Number of Participants With Markedly Abnormal Clinical Laboratory Tests

Description

Time Frame

Baseline up to Week 52

Secondary Outcome Measure Information:

Title

Change From Baseline in Office Trough Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit

Description

Time Frame

Baseline (End of Run-in Period, Week 0) and Weeks 12 (LOCF) and 52 (LOCF)

Title

Change From Baseline in Home Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit

Description

The change in home morning SPB and DBP measured at End of Week 12, End of Treatment (Up to Week 52) relative to baseline.

Time Frame

Baseline (End of Run-in Period, Week 0), End of Week 12 and End of Treatment (Up to Week 52)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

20 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements. The participant signs and dates a written informed consent form prior to the initiation of any study procedures. The participant has essential hypertension. The participant has an office sitting systolic blood pressure (SBP) of <180 mmHg and office sitting diastolic blood pressure (DBP) of < 110 mmHg at the start of the run-in period (Week -4). Participants receiving combined therapy with a 3-drug antihypertensive within 4 weeks prior to the start of the run-in period is required to have an office sitting SBP of < 160 mmHg and an office sitting DBP of < 100 mmHg. The participant's office sitting blood pressure at Week -2 and at the end of the run-in period (Week 0) need to be either: Participants without concurrent diabetes mellitus or chronic kidney disease (CKD)*: Sitting SBP of ≥ 140 mmHg or sitting DBP of ≥ 90 mmHg Participants with concurrent diabetes mellitus or CKD*: Sitting SBP of ≥ 130 mmHg or sitting DBP of ≥ 80 mmHg. Estimate glomerular filtration rate according to creatinine (eGFRcreat) of <60 mL/min/1.73 m^2, or urinary albumin (spot urine) of ≥30 μg/mL in laboratory tests performed at Week -2 of the run-in period, and diagnosed with CKD by the investigator or subinvestigator. The participant has an office sitting SBP of < 160 mmHg and office sitting DBP of < 100 mmHg at the end of the run-in period (Week 0). The participant is male or female, aged 20 years or older at the time of providing informed consent. The participant is an outpatient. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agree to use routinely adequate contraception from signing of informed consent through 1 month following the end of the study. Exclusion Criteria: The participant has received any study drugs within 12 weeks prior to the start of the run-in period. The participant has participated in another clinical study or a post-marketing study within 30 days prior to the start of the run-in period. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g. spouse, parent, child, sibling), or may consent under duress. The participant requires taking prohibited concomitant drugs during the study. The participant has a history of hypersensitivity or allergies to TAK-536, AML, HCTZ, any thiazide diuretic or analog, any dihydropyridine drug, or any analog of TAK-536TCH. The participant is judged by the investigator or subinvestigator to be in danger of experiencing an excessive increase in blood pressure when changing or discontinuing premedication. The participant received combination therapy with antihypertensive drugs of the 3 ingredients contained in TAK-536TCH. The participant received combined therapy with antihypertensive drugs, including 4 or more components, within 4 weeks prior to the start of the run-in period. The participant has secondary or malignant hypertension. The participant has a difference of ≥ 20 mmHg between left and right arms in office sitting SBP at the start of the run-in period (Week -4). The participant has apparent white coat hypertension or exhibits a white coat effect. . The participant has a day-night reversed lifestyle, such as those working during the night. The participant has sleep apnea syndrome requiring treatment. The participant has any of the following cardiovascular diseases: Cardiac disease: Myocardial infarction*, coronary arterial revascularization*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage*, transient ischemic attack* Vascular disease: Peripheral artery disease with intermittent claudication, artery dissection, aneurysm Advanced hypertensive retinopathy: With bleeding or exudate/papilledema** * Occurring or performed within 24 weeks of the start of the run-in period ** Observed within 24 weeks of the start of the run-in period The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN). The participant has a clinically severe renal disorder (e.g., eGFRcreat in laboratory tests performed at Week -2 of run-in period < 30 mL/minute/1.73 m^2). The participant's body fluid sodium or potassium level is markedly low* or high*. *Based on normal ranges The participant has gout or a history of gout within 24 weeks of the start of the run-in period or has hyperuricemia requiring drug treatment. The participant has uncontrolled diabetes (e.g., HbA1c ≥ 7.4% in laboratory tests performed at Week -2 of the run-in period). The participant has a malignant tumor. If female, the participant is pregnant or lactating or before giving informed consent, intending to become pregnant or donate ova during or within 1 month after participating in the study. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the run-in period. The participant who, in the opinion of the investigator or subinvestigator, is unsuitable for any other reason.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Medical Director Clinical Science

Organizational Affiliation

Takeda

Official's Role

Study Director

Facility Information:

City

Nagoya-shi

State/Province

Aichi

Country

Japan

City

Chiba-shi

State/Province

Chiba

Country

Japan

City

Itojima-shi

State/Province

Fukuoka

Country

Japan

City

Kouriyama-shi

State/Province

Fukushima

Country

Japan

City

Sapporo-shi

State/Province

Hokkaido

Country

Japan

City

Amagasaki-shi

State/Province

Hyougo

Country

Japan

City

Tsukuba-shi

State/Province

Ibaragi

Country

Japan

City

Morioka-shi

State/Province

Iwate

Country

Japan

City

Sakaide-shi

State/Province

Kagawa

Country

Japan

City

Takamatsu-shi

State/Province

Kagawa

Country

Japan

City

Kawasaki-shi

State/Province

Kanagawa

Country

Japan

City

Kyoto-shi

State/Province

Kyoto

Country

Japan

City

Uji-shi

State/Province

Kyoto

Country

Japan

City

Sendai-shi

State/Province

Miyagi

Country

Japan

City

Hirakata-shi

State/Province

Osaka

Country

Japan

City

Osaka-shi

State/Province

Osaka

Country

Japan

City

Takatsuki-shi

State/Province

Osaka

Country

Japan

City

Saitama-shi

State/Province

Saitama

Country

Japan

City

Tokorozawa-shi

State/Province

Saitama

Country

Japan

City

Yaizu-shi

State/Province

Shizuoka

Country

Japan

City

Chiyoda-ku

State/Province

Tokyo

Country

Japan

City

Choufu-shi

State/Province

Tokyo

Country

Japan

City

Kodaira-shi

State/Province

Tokyo

Country

Japan

City

Koutou-ku

State/Province

Tokyo

Country

Japan

City

Setagaya-ku

State/Province

Tokyo

Country

Japan

City

Shinagawa-ku

State/Province

Tokyo

Country

Japan

City

Shinjuku-ku

State/Province

Tokyo

Country

Japan

City

Choufu-shi

Country

Japan

City

Kawasaki-shi

Country

Japan

City

Koutou-ku

Country

Japan

City

Morioka-shi

Country

Japan

City

Sakaide-shi

Country

Japan

City

Setagaya-ku

Country

Japan

City

Shinagawa-ku

Country

Japan

City

Shinjuku-ku

Country

Japan

City

Tsukuba-shi

Country

Japan

City

Uji-shi

Country

Japan

City

Yaizu-shi

Country

Japan

12. IPD Sharing Statement

Citations:

PubMed Identifier

29235365

Citation

Rakugi H, Shimizu K, Nishiyama Y, Sano Y, Umeda Y. A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. Blood Press. 2018 Jun;27(3):125-133. doi: 10.1080/08037051.2017.1412797. Epub 2017 Dec 13. Erratum In: Blood Press. 2018 Jun;27(3):184.

Results Reference

derived

Learn more about this trial

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

We'll reach out to this number within 24 hrs